SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, inheriting Bitcoin's decentralized ethos and aiming to onboard retail investors to the Bitcoin ecosystem. The community emphasizes its fair launch and potential to surpass other meme coins like DOGE by leveraging Bitcoin's network security; discussions also highlight the backing from $CBLO.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to news of a land sale boosting its NAV, with the community focusing on its low float and potential for a significant upward move. Chatter suggests the stock is undervalued, with some anticipating a potential squeeze and rapid price increase if key resistance levels are broken. Investors are closely watching for a breakout and considering potential entry points.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid community chatter about a potential licensing deal and speculation around upcoming data releases. Discussions revolve around the company's strategic direction and the potential impact of ongoing clinical trials for their lung cancer drug. Bullish investors are highlighting insider buying and the drug's potential to compete with existing treatments.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK.X is trending amid community discussions around potential rallies and resistance levels, with some traders looking at opportunities to increase their positions. There is chatter regarding a large $25 million investment into Bonk coins, and potential implications. Comparisons to other meme coins like DOGE.X and SHIB.X remain prevalent.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as community members highlight its unique protocol that rewards holders with $SOL.X based on trading volume, promoting it as a DeFi savings account. The community is rallying behind the token's resilience and potential for long-term growth, emphasizing its community-led nature and new partnerships. Discussions also highlight the shift towards web 4.0 protocols rewarding user belief rather than hype, positioning $IMG.X as a leading example on the Solana blockchain.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

IDYA is trending due to positive Phase 2 data and a successful FDA meeting regarding its uveal melanoma treatment, darovasertib, potentially leading to accelerated approval. Community members are focused on the drug's efficacy and potential for eye preservation, as well as upcoming presentations. Analysts are also weighing in with positive ratings and price target adjustments, citing a promising pipeline beyond its lead asset.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as the crypto community rallies behind Dog of Bitcoin ($DOG), viewing it as more than just a memecoin but as a movement rooted in Bitcoin's principles. Supporters believe $DOG embodies a fair, decentralized, and community-driven approach, positioning it as a potential successor to Dogecoin and a significant player in the Bitcoin Layer-2 ecosystem.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapport Therapeutics ($RAPP) is trending due to anticipation surrounding the upcoming topline results for its RAP-219 Phase 2a trial in focal onset seizures. The community is discussing whether the news will be positive and lead to further gains, or if it will be a "sell the news" event after the recent after-hours surge. Some traders are also noting the stock's low float and potential for volatility.

Vulcan Materials Co. engages in the production of construction aggregates. It operates through the following segments: Aggregates, Asphalt, and Concrete. The Aggregates segment produces and sells aggregates and related products and services. The Asphalt segment relates to the production and selling of asphalt mix in Arizona, California, New Mexico, Tennessee, and Texas. The Concrete segment refers to the production and selling of ready-mixed concrete in California, Maryland, and Virginia in addition to the U.S. Virgin Islands and Washington D.C. The company was founded in 1909 and is headquartered in Birmingham, AL.

Vulcan Materials Co

Vulcan Materials' Q2 earnings results and future growth potential are driving community discussion. While some analysts are adjusting price targets, others highlight the company's strong market position and potential to benefit from infrastructure spending. A microcap stock, CAPS, is also being discussed as a peer comparison within the building materials sector, especially in terms of revenue growth.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending as the community rallies around its active development team, which is focused on building utility and staking options. Community members are excited about upcoming burns and contests, and many believe the coin is undervalued. The conversation highlights the coin's strong community and dedication to breaking into the top trending spot.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer TuHURA Biosciences...

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor

TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor TuHURA Biosciences Enters into Exclusivity and Right of...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 08/04/2024

Gagnants
L'action Kineta (NASDAQ:KA) a mont lundi de 16,77% 0,63 dollars lors de la session after-market.
Le titre Windtree Therapeutics (NASDAQ:WINT) a mont de 14,63% 0,47 dollars.
Le titre...

12 titoli sanitari in movimento, after-market del 08/04/2024

Titoli in rialzo
Le azioni di Kineta (NASDAQ:KA) hanno guadagnato l'11,21% a 0,60 dollari durante la sessione after-market di luned .
Le azioni di Finch Therapeutics Gr (NASDAQ:FNCH) sono salite...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 03/04/2024

Gagnants
L'action Kineta (NASDAQ:KA) a grimp mercredi de 8,46% 0,58 dollars lors de la session after-market.
Le titre Simulations Plus (NASDAQ:SLP) a mont de 8,07% 41,50 dollars. La soci t a...

Kineta, Inc. (NASDAQ:KA) Short Interest Update

Kineta, Inc. (NASDAQ:KA  Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 75,300 shares, a...

KA Stock Earnings: Kineta Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
KA stock results show that Kineta beat analyst estimates for earnings per share the fourth quarter of 2023.
The post KA Stock Earnings...

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose...

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of...

Week in Review: Most popular stories on GeekWire for the week of Feb. 25, 2024

Get caught up on the latest technology and startup news from the past week. Here are the most popular stories on GeekWire for the week of Feb. 25, 2024.
Sign up to receive these updates every Sunday...

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.

Current Price	$0.3361
Prev Close	$0.29
Open	$0.3041
Dividend Yield	0.00%
50-Day Moving Average	$0.2709
Beta	0.59
Avg. Volume	14,614.48
PE Ratio	-0.50

52-Week High	$1.15
52-Week Low	$0.1806
Market Capitalization	$4.55M
EPS (Annual)	-$1.42
Price to Book	-0.34
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KA
Kineta Inc

Feed

News

Sentiment

Fundamentals

Info

Latest KA News

KA Kineta Inc